🇺🇸 FDA
Pipeline program

Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

WO41535

Phase 3 small_molecule active

Quick answer

Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion. for High-risk hepatocellular carcinoma (HCC) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
High-risk hepatocellular carcinoma (HCC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials